Bright Peak Therapeutics Inc. has raised $90 million in a series C financing. Proceeds will be used to accelerate a pipeline of next-generation immunotherapies and advance BPT-567 into a phase I/IIa trial.
Bright Peak Therapeutics Inc. has licensed rights to use Livzon Mabpharm Inc.’s anti-PD-1 candidate, LZM-009, to develop its own PD-1 targeted immunocytokines (PD-1 ICs). Bertolt Kreft, chief scientific officer for Bright Peak, told BioWorld that Livzon’s phase II anti-PD-1 “exhibits a promising initial safety and efficacy profile, making it well-suited to the task.
Bright Peak Therapeutics Inc. has licensed rights to use Livzon Mabpharm Inc.’s anti-PD-1 candidate, LZM-009, to develop its own PD-1 targeted immunocytokines (PD-1 ICs). Bertolt Kreft, chief scientific officer for Bright Peak, told BioWorld that Livzon’s phase II anti-PD-1 “exhibits a promising initial safety and efficacy profile, making it well-suited to the task.
The hefty $107.5 million series B financing disclosed June 10 by Synthekine Inc. underscored Wall Street’s interest in engineered cytokines, where an army of companies is developing prospects at varying stages – including Bright Peak Therapeutics Inc., which pulled down a series B in almost exactly the same amount as Synthekine, and on the same day.
Bright Peak Therapeutics Inc. closed a $107 million series B round to progress a pipeline of engineered cytokines, which are produced using a chemical synthesis method instead of classical recombinant protein production approaches.
DUBLIN – Versant Ventures is committing $35 million in series A funding to Bright Peak Therapeutics Inc., which is developing a pipeline of engineered cytokines that are produced using a novel chemical synthesis technique rather than the recombinant methods that have underpinned more than four decades of biotechnology development.
